UNSPSC 51432403: Zofenopril

This classification denotes an ace inhibitor with the molecular formula C22H23NO4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 290ZY759PI chemically known as r-proline, 1-(3-(benzoylthio)-2-methyl-1-oxopropyl)-4-(phenylthio)-, (1(r*),2.alpha.,4.alpha.)- but generally known as zofenopril, which bears US NIH Compound Identifier 92400. European Medicines Agency schedules Zofenopril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00170MIG.

UNSPSC 51432403 Zofenopril is a Commodity code that classifies individual pharmaceutical products supplied to state and local government health care and emergency response operations. State and local buyers use this code to procure specific medications for fire rescue services, health and human services agencies, and multistate cooperative purchasing programs. The work involves supplying branded or generic pharmaceutical formulations that meet FDA manufacturing standards, expiration-date requirements, and cold-chain or storage specifications. Issuing bodies include city fire departments (purchasing on behalf of rescue operations), state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across multiple state and local government facilities. The code sees activity from municipal purchasing offices, state pharmacy benefit programs, and special-purpose cooperative purchasing entities.

Recent activity centers on Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications due April 8, 2026, requesting specific formulations including Labetalol HCI, Epinephrine, Adenosine, and Diltiazem for Tampa Fire Rescue, with an estimated contract value of $40,000 and a Small Local Business Enterprise sheltered-market set-aside offering a 5 percent bid discount not to exceed $10,000. The Texas Health and Human Services Commission issued RFI HHS0017013 (closed April 3, 2026) exploring direct-to-manufacturer prescription programs to support its Therapeutic Pharmacy Initiative outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, solicited generic multi-source pharmaceuticals and OTC products via RFP S1070000015802 (due March 26, 2026) for distribution through three authorized wholesalers serving state and local government facilities across Minnesota and Oregon, with contract effectiveness July 1, 2026. Cooperative purchasing vehicles and multistate alliances appear to represent significant procurement volume, alongside individual jurisdiction emergency-response purchases.